Home/Indications/Musculoskeletal/Spasticity

Spasticity

Musculoskeletal 1 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Market Leaders

AbbVie

original drugs

Phase 3 Readouts Pro

4 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Recombinant Botulinum Toxin Type A for injection (YY001)

Chongqing Claruvis Pharmaceutical Co., Ltd.

Estimated · fresh NCT06783114

Q2 2027

Recombinant botulinum toxin type A for injection (YY001)

Chongqing Claruvis Pharmaceutical Co., Ltd.

Estimated · fresh NCT07478822

Q1 2028

Arbaclofen

RVL Pharmaceuticals, Inc.

Estimated · fresh NCT05179577

Unlock 1 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 1 mechanisms across 3 industry trials with a known mechanism of action.

See full pipeline →

Acetylcholine Release Inhibitor

3 trials 2 sponsors

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

60 industry-sponsored trials across 24 sponsors

Showing 7 of 7 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Ipsen	AboBoNT-A	—	COMPLETED	2025-08-26	NCT04936542
MedtronicNeuro	intrathecal baclofen	—	COMPLETED	2016-09	NCT01032239
Medy-Tox	Ultrasonography guidance injection of Meditoxin®.	—	COMPLETED	2016-08-16	NCT02757404
Ipsen	Botulinum toxin type A	—	COMPLETED	2016-03	NCT02321436
Medy-Tox	Meditoxin	—	COMPLETED	2014-10-31	NCT03908580
Jazz Pharmaceuticals	Sativex	—	COMPLETED	2013-05	NCT01964547
Medy-Tox	Botulinum Toxin Type A	—	COMPLETED	2011-02	NCT01256021

Showing 40 of 40 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Chongqing Claruvis Pharmaceutical Co., Ltd.	Recombinant Botulinum Toxin Type A for injection (YY001)	—	RECRUITING	2026-09-30	NCT06783114
Chongqing Claruvis Pharmaceutical Co., Ltd.	Recombinant botulinum toxin type A for injection (YY001)	—	RECRUITING	2027-06-01	NCT07478822
Merz Pharmaceuticals GmbH	NT 201	—	ACTIVE NOT RECRUITING	2025-06-19	NCT03992404
Supernus Pharmaceuticals, Inc.	Phase 2; Low Dose MYOBLOC	—	ACTIVE NOT RECRUITING	2023-07-01	NCT04815967
RVL Pharmaceuticals, Inc.	Arbaclofen	—	NOT YET RECRUITING	2028-01	NCT05179577
Huons Co., Ltd.	HU-014 Inj	—	COMPLETED	2023-01-03	NCT05289921
RVL Pharmaceuticals, Inc.	Arbaclofen	—	COMPLETED	2020-01-27	NCT03319732
RVL Pharmaceuticals, Inc.	Arbaclofen	—	COMPLETED	2018-12-03	NCT03290131
AbbVie	Botulinum Toxin Type A	—	COMPLETED	2018-09-03	NCT01603615
AbbVie	Botulinum Toxin Type A	—	COMPLETED	2018-08-25	NCT01603641
Medy-Tox	CORETOX®	—	COMPLETED	2018-06-30	NCT03289702
GSK	Botulinum toxin A (GSK1358820)	—	COMPLETED	2018-03-20	NCT03261167
Ipsen	Botulinum toxin type A	—	COMPLETED	2017-09-21	NCT02106351
Sun Pharma Advanced Research Company Limited	SPARC0921	—	COMPLETED	2017-08-25	NCT01457352
Merz Pharmaceuticals GmbH	IncobotulinumtoxinA (8 Units per kg body weight)	—	COMPLETED	2017-07-04	NCT02002884
Sun Pharma Advanced Research Company Limited	SPARC1104 modified dose regimen I	—	COMPLETED	2017-07	NCT01797185
AbbVie	botulinum toxin Type A	—	COMPLETED	2017-06-29	NCT01603602
AbbVie	botulinum toxin Type A	—	COMPLETED	2017-06-28	NCT01603628
Merz Pharmaceuticals GmbH	IncobotulinumtoxinA (16-20 Units per kg body weight)	—	COMPLETED	2017-01	NCT01905683
Piramal Critical Care, Ltd.	Gablofen® 3 mg/mL (baclofen injection)	—	COMPLETED	2016-08	NCT01520545
Merz Pharmaceuticals GmbH	IncobotulinumtoxinA (16 Units per kg body weight)	—	COMPLETED	2015-08	NCT01893411
Ipsen	Botulinum toxin type A	—	COMPLETED	2015-04	NCT01251367
Ipsen	Botulinum toxin type A	—	COMPLETED	2015-01	NCT01251380
RVL Pharmaceuticals, Inc.	arbaclofen	—	COMPLETED	2014-12	NCT01844232
Merz Pharmaceuticals GmbH	IncobotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	COMPLETED	2014-09	NCT01603459
AbbVie	botulinum toxin Type A	—	COMPLETED	2014-09	NCT01575054
Merz Pharmaceuticals GmbH	IncobotulinumtoxinA (400 Units)	—	COMPLETED	2014-08	NCT01464307
Daewoong Pharmaceutical Co. LTD.	Botulinum toxin type A	—	COMPLETED	2014-05	NCT01945684
Hugel	Botulinum toxin type A(Botulax®)	—	COMPLETED	2014-05	NCT01915459
RVL Pharmaceuticals, Inc.	arbaclofen	—	COMPLETED	2014-04	NCT01743651
Ipsen	Botulinum toxin type A	—	COMPLETED	2014-02	NCT01249417
Ipsen	Botulinum toxin type A	—	COMPLETED	2013-12	NCT01249404
Merz Pharmaceuticals GmbH	IncobotulinumtoxinA (400 Units)	—	COMPLETED	2013-03	NCT01392300
Medy-Tox	Botulinum toxin type A	—	COMPLETED	2012-01	NCT01313767
GSK	Botulinum toxin type A	—	COMPLETED	2011-12	NCT01205451
Jazz Pharmaceuticals	Sativex®	—	COMPLETED	2009-01	NCT00681538
AbbVie	onabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	TERMINATED	2015-12	NCT02145676
Ipsen	Botulinum toxin type A	—	TERMINATED	2015-03	NCT01682148
AbbVie	onabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	WITHDRAWN	2017-05	NCT02145689
Flowonix Medical	—	—	WITHDRAWN	2010-06	NCT01051128

Showing 7 of 7 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Elpida Therapeutics SPC	MELPIDA	—	RECRUITING	2028-10-01	NCT05518188
Ipsen	IPN10200	—	RECRUITING	2029-03-30	NCT04752774
Revance Therapeutics, Inc.	DAXI for injection 250 U	—	COMPLETED	2020-11-23	NCT03821402
Sun Pharma Advanced Research Company Limited	SPARC1103 low dose	—	COMPLETED	2017-04-28	NCT02027025
Acorda Therapeutics	Tizanidine	—	COMPLETED	2014-02	NCT01839279
Impax Laboratories, LLC	IPX056	—	COMPLETED	2010-01	NCT00914290
Teva GTC	sublingual tizanidine 12 mg	—	TERMINATED	2008-12	NCT00464958

Showing 6 of 6 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Motric Bio	MTR-601	—	COMPLETED	2024-10-16	NCT06117020
Jetema Co., Ltd.	JTM201 in normal saline	—	COMPLETED	2024-04-22	NCT07292025
CKD Bio Corporation	CKDB-501A	—	COMPLETED	2022-12-08	NCT05382767
Medy-Tox	CORETOX®	—	COMPLETED	2017-09-29	NCT05164003
AbbVie	ABBV-950	—	TERMINATED	2024-06-02	NCT05956509
Acorda Therapeutics	Zanaflex Capsules	—	TERMINATED	2012-03	NCT01405950

Novel Drugs by Company (New molecular entities)

AbbVie 1 drug

BOTOX

OnabotulinumtoxinA

BLA 1991

Reformulations (7 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.